Literature DB >> 20333461

Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population.

Simona Ognjanovic1, Jennifer Yamamoto, Barbara Saltzman, Adrian Franke, Miodrag Ognjanovic, Lance Yokochi, Thomas Vogt, Robert Decker, Loïc Le Marchand.   

Abstract

Chronic inflammation, which is suspected to play a role in the development of colorectal cancer (CRC), has rarely been studied in colorectal adenoma. We investigated the inter-relationships of serum levels of the inflammatory proteins CRP and in IL-6, single nucleotide polymorphisms (SNPs) in the CRP (rs1205, rs1130864, rs1800947) and IL6 (rs1800795) genes, and lifestyle factors with colorectal adenoma in a sigmoidoscopy-based case-control study of 271 adenoma cases and 539 age-, sex-, and race/ethnicity-matched controls in Hawaii. We found no association of serum CRP or IL-6 levels with the risk of adenoma. A multiple regression with stepwise selection identified elevated BMI, Caucasian and Native Hawaiian versus Japanese race/ethnicity, and current smoking as being associated with significantly higher serum CRP and IL-6 levels. Female versus male gender was also associated with higher CRP levels and older age with higher IL-6 levels. The C allele of rs1205 and the A allele of rs1130864 were significantly associated with higher serum CRP levels (p (trend): 0.0002 and 0.01, respectively), as well as with a decreased adenoma risk [rs1205: OR for CT and CC vs. TT = 0.69 (95% CI: 0.48-0.98) and 0.53 (0.34-0.83), respectively, p (trend) = 0.008; rs1130864: OR for GA and AA versus GG = 0.65 (0.45-0.93) and 0.74 (0.31-1.76), respectively, p (trend) = 0.04]. The findings of lower serum CRP and IL-6 levels in Japanese (a group with a high CRC risk) and of a decreased adenoma risk observed for alleles associated with higher circulating CRP levels suggest a protective effect for CRP in early colorectal neoplasia that warrants further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333461     DOI: 10.1007/s10552-010-9540-7

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  38 in total

1.  Single-nucleotide polymorphisms at five loci are associated with C-reactive protein levels in a cohort of Filipino young adults.

Authors:  Ghenadie Curocichin; Ying Wu; Thomas W McDade; Christopher W Kuzawa; Judith B Borja; Li Qin; Ethan M Lange; Linda S Adair; Leslie A Lange; Karen L Mohlke
Journal:  J Hum Genet       Date:  2011-09-22       Impact factor: 3.172

Review 2.  IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review.

Authors:  Yong Yu; Wenjun Wang; Song Zhai; Shuangsuo Dang; Mingzhu Sun
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

3.  C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Authors:  Andrew T Chan; Camelia S Sima; Ann G Zauber; Paul M Ridker; Ernest T Hawk; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2011-08

4.  Comparison of plasma levels of nutrient-related biomarkers among Japanese populations in Tokyo, Japan, São Paulo, Brazil, and Hawaii, USA.

Authors:  Motoki Iwasaki; Adrian A Franke; Gerson S Hamada; Nelson T Miyajima; Sangita Sharma; Junko Ishihara; Ribeka Takachi; Shoichiro Tsugane; Loïc Le Marchand
Journal:  Eur J Cancer Prev       Date:  2015-03       Impact factor: 2.497

5.  C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study.

Authors:  Seth D Crockett; Leila A Mott; Elizabeth L Barry; Jane C Figueiredo; Carol A Burke; Gwen J Baxter; Robert S Sandler; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-21

6.  Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.

Authors:  Upender Manne; Trafina Jadhav; Balananda-Dhurjati Kumar Putcha; Temesgen Samuel; Shivani Soni; Chandrakumar Shanmugam; Esther A Suswam
Journal:  Curr Colorectal Cancer Rep       Date:  2016-09-20

7.  Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies.

Authors:  Jason B Douglas; Debra T Silverman; Stephanie J Weinstein; Barry I Graubard; Michael N Pollak; Yuzhen Tao; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-20       Impact factor: 4.254

8.  A prospective evaluation of C-reactive protein levels and colorectal adenoma development.

Authors:  Marc J Gunter; Amanda J Cross; Wen-Yi Huang; Frank Z Stanczyk; Mark Purdue; Xiaonan Xue; Robert Schoen; Paul J Limburg; Arthur Schatzkin; Rashmi Sinha; Richard B Hayes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-06       Impact factor: 4.254

9.  Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Authors:  Sarah Kraus; Simone Hummler; Nadir Arber; Cornelia M Ulrich; Adetunji T Toriola; Elizabeth M Poole; Dominique Scherer; Jana Kotzmann; Karen W Makar; Dina Kazanov; Lior Galazan; Inna Naumov; Anna E Coghill; David Duggan; Biljana Gigic
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

10.  Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.

Authors:  James R Davenport; Qiuyin Cai; Reid M Ness; Ginger Milne; Zhiguo Zhao; Walter E Smalley; Wei Zheng; Martha J Shrubsole
Journal:  Mol Carcinog       Date:  2015-08-31       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.